Journals / Retina-Vitreus / 2017 / Cilt: 26 - Sayı: 4

Coats’ Disease and Treatment Strategies

Coats’ Hastalığı ve Tedavi Yaklaşımları

Pages
301–306
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Although laser photocoagulation and cryotherapy are the main treatment modalities in early stages of the disease, intravitreal steroid and anti- vascular endothelial growth factor injections in addition to ablative therapy may help to achieve better anatomical and visual outcome.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Purpose: To review the clinical features and treatment strategies of patients with the diagnosis of Coats’ disease (CD).
📊
Key Findings & Data:Material and Methods: Files of twenty-nine patients with CD diagnosed between June 1997 and April 2015 were reviewed retrospectively.
💡
Conclusion & Impact:Although laser photocoagulation and cryotherapy are the main treatment modalities in early stages of the disease, intravitreal steroid and anti- vascular endothelial growth factor injections in addition to ablative therapy may help to achieve better anatomical and visual outcome.
🔬Design:Review & Systematic Survey
📍Scope:2015 Verileri
⚙️Variables:Domain Parameters

Abstract

Purpose: To review the clinical features and treatment strategies of patients with the diagnosis of Coats’ disease (CD). Material and Methods: Files of twenty-nine patients with CD diagnosed between June 1997 and April 2015 were reviewed retrospectively. Clinical features, treatment alternatives and results were evaluated. Results: Twenty- fi ve patients were male and four female. Mean age of the subjects was 10,3±13.9 (Range: 1 month-56 years) and mean follow up time was 2.8±3.1 years (Range; 6 month -14years). Thirty eyes of 29 patients were involved in the study. The involvement was unilateral in 28 patients and bilateral in one patient. Twelve of 30 eyes (40%) were diagnosed to have stage 2 disease, 9 eyes (30%) stage 3, 5 eyes (16.6%) stage 4 and 4 eyes (13.3%) had stage 5 disease. Where 12 of 21 eyes diagnosed to have stage 2 or 3 disease were received photocoagulation combined with adjuvant therapy (intravitreal injection), 9 eyes were treated with only laser photocoagulation therapy. While eyes diagnosed to have stage 4 disease were followed up without any treatment, one of the eyes which diagnosed to have stage 5 disease, enucleation surgery was performed for defi nitive diagnosis from retinablostoma. Evisceration surgery was performed to the other one because of painful eye due to CH. Best-corrected visual acuity did not change in 9 eyes, decreased in 8 eyes and increased only in 4 eyes diagnosed to have stage 2 or 3 disease at the end of the last visit. Conclusion: Successful visual outcome usually depends on the disease stage in eyes with CD. Although laser photocoagulation and cryotherapy are the main treatment modalities in early stages of the disease, intravitreal steroid and anti- vascular endothelial growth factor injections in addition to ablative therapy may help to achieve better anatomical and visual outcome.

Özet

Amaç: Coats' hastalığı (CH) tanısı ile takip edilmekte olan hastaların klinik özelliklerinin gözden geçirilerek tedavi seçeneklerinin değerlendirilmesi.Gereç ve Yöntemler: Haziran 1997 - Nisan 2015 tarihleri arasında CH tanısı konulan 29 hastanın dosyaları retrospektif olarak incelenerek hastalığın klinik özellikleri, uygulanan tedavi ve sonuçları değerlendirildi.Bulgular: Hastaların 25' i (%86.2) erkek, 4'ü (%13.8) kadındı. Ortalama yaş 10,3±13.9 (Dağılım: 1 ay-56 yaş) yıl ve ortalama takip süresi 2.8±3.1 yıl (Dağılım;6 ay-14 yıl) olarak bulundu. Çalışmaya 29 hastanın 30 gözü dahil edildi. 28 hastada (%96.5) tek gözde tutulum mevcutken, 1 hastada (%3.5) her iki gözde hastalık mevcuttu. 12 göz (%40) evre 2 hastalık, 9 göz (%30) evre 3, 5 göz (%16.6) evre 4 ve 4 göz (%13,3) evre 5 hastalık tanısıyla takip edilmekteydi. Evre 2 ya da 3 tanılı 21 gözden 12'sine lazer fotokoagulasyonla birlikte adjuvan tedavi (intravitreal enjeksiyon), 9 göze sadece lazer fotokoagulasyon tedavisi uygulanmıştı. Evre 4 tanılı gözler tedavisiz izlenirken; evre 5 tanılı 2 gözden birine retinoblastom ayırıcı tanısı için enükleasyon, diğerine ise CH ikincil ağrılı göz olması nedeni ile evisserasyon cerrahisi yapılmıştı. Evre 2 ve 3 hastalık tanılı 21 gözün izlem süresince en iyi düzeltilmiş görme keskinliğinin 9 gözde stabil kaldığı, 8 gözde kötüleştiği ve yalnızca 4 gözde artış olduğu görüldü. Sonuç: Coats' hastalığında görsel başarı hastalığın ilk tanı anındaki evresine göre değişmektedir. Fotokoagulasyon ve kriyoterapi tedavinin esasını oluşturmakla birlikte intravitreal steroid ve anti-vasküler endotelyal büyüme faktörü enjeksiyonlarının ablasyon tedavisinin başarısını artırabilme olasılığı mevcuttur

🔖

Cite This Article

ÜNLÜ, B., PARLAK, M., YAMAN, A., BERK, A. T., ÖZER, E., SAATCİ, A. O., AYHAN, Z. (2017). Coats’ Disease and Treatment Strategies. Retina-Vitreus, Cilt: 26 - Sayı: 4, 301–306. https://ajindex.com/articles/304958

References (17)

  1. Shields JA, Shields CL, Honavar SG et al. Clinical variations and complications of Coats’ disease in 150 cases: The 2000 Sanford Gifford memorial lecture. Am J Ophthalmol 2001;131:561-571
  2. Orphanet Report Series; Prevalance and incidence of rare diseases. March 2016, Number 1. http://www.orpha.net/orphacom/cahiers/ docs/GB/ Prevalence of rare diseases by alphabetical list.pdf 3. Black GC, Perveen R, Bonshek R et al. Coats’ disease of the retina (unilateral retinal telangiectasis) caused by somatic mutation in the NDP gene: a role for norrin in retinal angiogenesis. Hum Mol Genet 1999;8:2031–2035
  3. Fernandes BF, Odashiro AN, Maloney S et al. Clinical histopathological correlation in a case of coats’ disease. Diagn Pathol 2006;1:24
  4. Berk TA, Oner HF, Saatci AO. Underlying pathologies in secondary strabismus. Strabismus 2000;8:69-75
  5. Mulvihill A, Morris B. A population-based study of Coats disease in the United Kingdom II: investigation, treatment, and outcomes. Eye (Lond) 2010;24:1802-1807
  6. Saatci AO, Tekin NF, Saatci I et al. Coats’ disease and calcifi cation: a case report. Metab Pediatr Syst Ophthalmol 1996-1997;19- 20:21-22
  7. Shields JA, Shields CL, Honavar Sg et al. Classifi cation and management of Coats disease. The 2000 Proctor Lecture. Am J Ophthalmol 2001;131:572–583
  8. Kocaoğlan H, Acar MA, Ünlü N et al. Coats hastalığında lazer fotokoagulasyon tedavisi sonuçları. Ret-Vit 1999;8:129-34
  9. Erol N, Topbaş S. Coats hastalığında kriyoterapi ve lazer fotokoagulasyon tedavisinin etkinliği. Ret-Vit 2010;18:46-51
  10. Durukan AH. Coats hastalığı. Ret-Vit 2012;20:115-119 (Özel sayı)
  11. Haik BG. Advanced Coats’ disease. Trans Am Ophthalmol Soc 1991;89:371-476
  12. Char DH. Coats’ syndrome: long term follow up. Br J Ophthalmol 2000;84:37-39
  13. Silodor SW, Augsburger JJ, Shields JA et al. Natural history and management of advanced Coats’ disease. Ophthalmic Surg 1988;19:89-93
  14. Parlak M, Saatci AO. A review of intravitreal treatment alternatives used as an adjunctive therapy in Coats’ disease. Int J Ophthalmic Res 2015;1:71-76
  15. Bergstrom CS, Hubbard GB 3rd. Combination intravitreal triamcinolone injection and cryotherapyfor exudative retinal detachments in severe Coats disease. Retina 2008;28:33-37
  16. Othman IS, Moussa M, Bouhaimed M. Management of lipid exudates in Coats disease by adjuvant intravitreal triamcinolone: effects and complications. Br J Ophthalmol 2010;94:606-610
  17. Ghazi NG, Al Shamsi H, Larsson J et al. Int